health
January 29, 2026
Inside Nvidia and Eli Lilly's $1bn AI Drug Discovery Lab
The tech giant and pharmaceutical manufacturer are building foundation models for biology and chemistry, using physical AI to accelerate drug development
TL;DR
- Nvidia and Eli Lilly are investing $1 billion in an AI co-innovation laboratory.
- The lab will focus on developing AI models for biology and chemistry using Nvidia's BioNeMo platform and Vera Rubin architecture.
- The partnership aims to accelerate drug discovery, development, and manufacturing through advanced AI and robotics.
- A continuous learning system will connect Eli Lilly's wet labs with computational dry labs for 24/7 AI-assisted experimentation.
- The initiative includes talent acquisition, infrastructure development, and computational resources in the San Francisco Bay Area.
- The collaboration extends to clinical development, manufacturing, and commercial operations, exploring digital twins and agentic AI.
Continue reading the original article